VivoSim Labs, Inc. (VIVS): EPS (Basic)
-$5.35
Year ended 2026-03-31
| Period ended | EPS (Basic) | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | -$5.35 | n/m | 2026-07-14, From 2025-04-01 |
| 2025-03-31 | -$1.70 | n/m | 2026-07-14, From 2024-04-01 |
| 2024-03-31 | -$19.25 | n/c | 2025-06-05, From 2023-04-01 |
| 2023-03-31 | -$1.98 | n/m | 2024-05-31, From 2022-04-01 |
| 2022-03-31 | -$1.32 | n/a | 2023-07-14, From 2021-04-01 |
EPS (Basic) at similar companies
| Company | Year ended | EPS (Basic) | Change YoY |
|---|---|---|---|
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | -$5.35 | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | -$0.80 | n/m |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | -$8.62 | n/m |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | -$1.86 | n/m |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $0.25 | 0.0% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | -$0.69 | n/m |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | -$2.73 | n/m |
| ImageneBio, Inc. (IMA) | 2025-12-31 | -$9.64 | n/m |
| Pluri Inc. (PLUR) | 2026-06-30 | -$2.44 | n/m |
Compare VIVS, ATYR, AIM, INMB side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗